Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Abstract Ovarian cancer is the most lethal gynaecologic malignancy. Although there are various subtypes of ovarian cancer, high-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian cancer deaths. Chemoresistance is the primary reason for the unfavourable prognosis of HGSOC. Kallistatin (K...
Main Authors: | Huan Wu, Rongrong Li, Zhiwei Zhang, Huiyang Jiang, Hanlin Ma, Cunzhong Yuan, Chenggong Sun, Yingwei Li, Beihua Kong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13048-019-0601-6 |
Similar Items
-
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2020-03-01) -
Serum kallistatin as a marker of severity of liver fibrosis in cirrhosis: A cross-sectional observational study
by: Seetaram Singh Kularaj, et al.
Published: (2022-01-01) -
Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice
by: Yuyu Yao, et al.
Published: (2018-11-01) -
Factors influencing serum chemerin and kallistatin concentrations in patients with alcohol-induced liver cirrhosis
by: Andrzej Prystupa, et al.
Published: (2019-03-01) -
Kallistatin leads to cognition impairment via downregulating glutamine synthetase
by: Yanlan Long, et al.
Published: (2024-04-01)